Currently, only osteoclast (OCL) inhibitors such as bisphosphonates (BPs) and the monoclonal antibody anti- receptor activator of nuclear factor-κB ligand (RANKL) denosumab are FDA-approved for the treatment of MM bone disease. The gene discussed is TNFSF11; the disease is Miyoshi myopathy.